Wall Street lauds Celgene's $7.2 billion Receptos buy

(Reuters) - Celgene Corp's effort to reduce dependence on its flagship cancer drug through the $7.2 billion (4.6 billion pounds) bet on Receptos Inc's potential blockbust...